{
  "image_filename": "table_p4_det_3_003.png",
  "image_path": "Zimmerman_et_al.__2023_/extracted/figures/table_p4_det_3_003.png",
  "image_type": "Table",
  "page_number": 4,
  "block_id": "det_3_003",
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "supports_claim": false,
  "explanation": "Table presenting baseline demographic and clinical characteristics of study participants receiving RIV4 (Flublok) or SD-IIV4, including race, sex, season, age group, influenza case status, and high-risk condition, with P-values for differences between groups. does not support the claim because the table only shows participant demographics and clinical characteristics, with no information on antigenic match to WHO- or FDA-selected flu strains.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table presenting baseline demographic and clinical characteristics of study participants receiving RIV4 (Flublok) or SD-IIV4, including race, sex, season, age group, influenza case status, and high-risk condition, with P-values for differences between groups.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only shows participant demographics and clinical characteristics, with no information on antigenic match to WHO- or FDA-selected flu strains.",
    "confidence_notes": null
  }
}